Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: Results from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health Research Network

Menopause

Volumn 20, Issue 3, 2013, Pages 261-268

  Joffe, Hadine ^a   Guthrie, Katherine A ^b   Larson, Joseph ^b   Cohen, Lee S ^a   Carpenter, Janet S ^c   Lacroix, Andrea Z ^b   Freeman, Ellen W ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Escitalopram; Hot flash; Randomized trial; Recurrence; Relapse; Selective serotonin reuptake inhibitor; Vasomotor symptoms

Indexed keywords

ESCITALOPRAM;

ADULT; ARTICLE; CLIMACTERIUM; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MENOPAUSE; MORBIDITY; NIGHT SWEAT; RANDOMIZED CONTROLLED TRIAL; RELAPSE; VASOMOTOR DISORDER; WITHDRAWAL SYNDROME;

EID: 85027957447     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e31826d3108     Document Type: Article

References (13)

1. Loprinzi CL, Diekmann B, Novotny PJ, Stearns V, Sloan JA. Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration. Menopause 2009;16: 184-187.
2. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305: 267-274.
3. Lindh-Astrand L, Brynhildsen J, Hoffman M, Hammar M. Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish populationYbased study. Menopause 2009;16: 1213-1217.
4. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102: 1233-1239.
5. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294: 183-193.
6. Brunner RL, Aragaki A, Barnabei V, et al. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause 2010; 17: 946-954.
7. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000;176: 363-368.
8. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001; 2: 297-307.
9. Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med 2007;22: 1596-1602.
10. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166: 1092-1097.
11. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28: 5147-5152.
12. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006;96: 1226-1235.
13. Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011; 117: 1095-1104.